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Abstract 
In colorectal cancer, oncogenic mutations transform a hierarchically organized and homeostatic 
epithelium into invasive cancer tissue. To define differences in cellular composition between the 
normal colon and colorectal cancer, and to map potential cellular interactions between tumor cells 
and their microenvironment, we profiled transcriptomes of >50,000 single cells from tumors and 
matched normal tissues of eight colorectal cancer patients. We find that tumor formation is 
accompanied by changes in epithelial, immune and stromal cell compartments in all patients. In the 
epithelium, we identify a continuum of five tumor-specific stem cell and progenitor-like populations, 
and persistent multilineage differentiation. We find multiple stromal and immune cell types to be 
consistently expanded in tumor compared to the normal colon, including cancer-associated 
fibroblasts, pericytes, monocytes, macrophages and a subset of T cells. We identify epithelial tumor 
cells and cancer-associated fibroblasts as relevant for assigning colorectal cancer consensus molecular 
subtypes. Our survey of growth factors in the tumor microenvironment identifies cell types responsible 
for increased paracrine EGFR, MET and TGF-β signaling in tumor tissue compared to the normal colon. 
We show that matched colorectal cancer organoids retain cell type heterogeneity, allowing to define 
a distinct differentiation trajectory encompassing stem and progenitor-like tumor cells. In summary, 
our single-cell analyses provide insights into cell types and signals shaping colorectal cancer cell 
plasticity. 
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Introduction 
All cells in the human body exist in contact with other cells in finely tuned microenvironments. 
Paracrine communication between cells ensures tissue homeostasis. Cancer cells are compromised in 
their ability to maintain homeostasis, as the oncogenic mutations activate signaling pathways cell-
intrinsically and render cancer cells less reliant on paracrine signals1. Furthermore, cancer cells induce 
remodeling of neighboring tissues, for instance by secreting growth factors not found in the normal 
environment2. Thirdly, cancer cells are often immunogenic or associated with inflammation, and 
therefore attract immune cells3. These processes intersect and result in the emergence of a 
qualitatively and quantitatively unbalanced cellular ecosystem in cancer tissue. Interactions between 
immune, stromal and cancer cells are critical for tumor progression and therapy response4,5. 
Colorectal cancer (CRC) most often initiates via mutations activating Wnt/β-catenin signaling that 
maintains stem cells in the normal colon epithelium, while subsequent mutations deregulate further 
signaling pathways such as the RAS-RAF-MEK-ERK signaling cascade6,7. Less frequently, CRC can arise 
by initiating mutations in BRAF, or from chronic inflammation increasing the mutation rate in the 
tissue. Regardless of the order of oncogenic mutations, genetic CRC drivers have direct and indirect 
effects on the cellular composition of CRC and its microenvironment. There is substantial evidence for 
the existence of tumor cell subpopulations in CRC. For instance, cancer stem cells with high clonogenic 
potential can be sorted from CRC based on surface markers like PROM1 (also known as CD133) or 
LGR58–10. Furthermore, CRC cells at the invasive front express matrix metalloproteinases such as MMP7 
and display epithelial-to-mesenchymal transition, in contrast to cells residing in more central locations 
in the tumor 11–13. However, it has not been investigated systematically how cell types and cell plasticity 
differ between the normal colon and CRC. 
Here, we use droplet-based single-cell RNA sequencing to profile cell types and their differentiation 
states in normal colon and tumor tissues of eight CRC patients, and in matching CRC organoids. We 
identify consistent changes occurring in epithelial differentiation programs between normal and tumor 
epithelium in the colon, resulting in the emergence of tumor-specific epithelial cell clusters expressing 
genes relevant for cancer traits such as stemness, invasion, and epithelial-to-mesenchymal transition. 
We also catalog cell types expanded in the tumor microenvironment, for instance, stromal cancer-
associated fibroblasts and several types of immune cells.  We provide evidence for cancer-cell-specific 
re-wiring of morphogenetic signaling informed by oncogenic mutations and differences in paracrine 
signaling networks.  
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Results 
Single-cell RNA sequencing of CRC 
To capture the cellular diversity in CRC and track changes from normalcy to disease, we performed 
single-cell transcriptome analysis of eight previously untreated CRC patients  (Fig. 1A). We utilized 
tissue samples that included the invasive tumor front and matched normal tissues (Supplementary Fig. 
1). Tumors under investigation encompass stages pTis (Tumor in situ) to pT4, that is, from cancer 
confined within the lamina propria to invasive through the visceral peritoneum, with or without 
metastasis, and with various locations along the cephalocaudal axis of the colon. Panel sequencing of 
genomic tumor DNA uncovered mutations in APC, KRAS and/or TP53 in tumors P008, P009, P013, P016, 
and P017; these mutations are characteristic for the canonical CRC progression pathway initiated by 
loss of APC. P007 harbored BRAFV600E and TP53 mutations; this mutational pattern is in line with a 
tumor initiated by BRAF activation. P008 carried a TP53 mutation and was colitis-associated. Tumor 
P014 contained putative driver mutations in APC, BRAF, HRAS, and PIK3CA, albeit at a lower frequency, 
suggesting the possibility of distinct subclones contributing to this tumor. 
We enzymatically dissociated the fresh normal and cancer tissues to single cells, produced single-cell 
transcriptome libraries from each tissue using a commercial droplet-based system, and sequenced the 
libraries to obtain transcriptomes covering 500 to 5,000 genes per cell. Singe-cell profiles were 
partitioned into epithelial, immune or stromal transcriptome subsets for each library, using known 
marker genes14, and then merged. We observed varying fractions of cell types per library, but stromal 
cells were generally less abundant (in total across all libraries: >25,000 epithelial cells; >25,000 immune 
cells and 2,691 stromal cells). Fluctuations in epithelial, immune or stromal cell abundance between 
libraries could reflect differences in tissue cell content or technical variances related to ischemic time 
during operation or the dissociation process. 
We observed that single-cell transcriptomes derived from all patients intermingled within the 
epithelial, immune, and stromal compartments  (Fig. 1B). When distinguishing normal versus tumor 
samples, distributions of single-cell profiles largely overlapped, although several regions within each 
plot were preferentially inhabited by transcriptomes derived from either normal or tumor tissues (Fig. 
1C). This indicates that our data are generally free from patient- or sample-specific batch effects 
confounding the cell type distributions, but that general differences occur between normal and tumor 
transcriptome distributions.  
Cell type census in CRC versus normal colon 
We next clustered the single-cell profiles of the epithelial, immune and stromal compartments, and 
used cell-type-specific signatures and marker genes to annotate cell types14 (Fig. 2A; Supplementary 
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Fig. 2 for genes over- or underrepresented between tumor and normal samples). In the normal 
epithelium, we identified a zone populated by profiles of undifferentiated cells with high activity of 
stem cell markers such as OLFM4 and transiently-amplifying proliferative markers. This region 
bordered on transcriptome clusters annotated as enterocyte progenitors, and, ultimately, mature 
absorptive enterocytes with high expression of markers such as KRT20 and FABP1. BEST4- and OTOP2-
expressing enterocytes formed a discrete cluster (Fig. 2A, identified by the lightest shade of green) 15. 
Further separate epithelial clusters were populated by profiles annotated as immature and mature 
secretory goblet cells defined by expression of MUC2, TFF1, and TFF3, and TRMP5-expressing tuft cells. 
In the tumor samples, the zone of undifferentiated epithelial cells was expanded by five largely tumor-
specific clusters (TC1-5, Fig. 2A, B; Supplementary Fig. 3 for data per patient).  In contrast, clusters of 
differentiated absorptive and secretory cell transcriptomes were reduced in size. Profiles representing 
tuft cells and BEST4/OTOP2-positive enterocytes were vastly underrepresented in the tumor cell 
libraries. 
We used immunofluorescence to verify the spatial distributions of epithelial cell types, using marker 
genes identified in the single-cell data (Fig. 2C, D). We detected the stem cell marker OLFM4 exclusively 
at the base of normal crypts. However, in tumor sections, OLFM4, as well as the proliferation marker 
MKI67, stained cells scattered throughout the epithelium, as validated by co-staining with the 
epithelial marker EPCAM. The goblet cell and enterocyte differentiation markers TFF3 and FABP1 
stained preferentially cells in the lower and upper crypt of the normal colon, respectively. In contrast, 
TFF3- and FABP1-positive tumor cell populations were not clearly organized in domains. Clusters of 
TFF3- and FABP1-positive cells that were largely negative for MKI67 suggest the presence of 
differentiated cells in CRC, in agreement with the single-cell sequencing data. 
The five tumor-specific epithelial cell clusters TC1 to TC5 were represented in different proportions in 
all eight CRCs under investigation (Fig. 2E). TC1 and TC2 were assigned as highly stem cell-like using 
prior classifiers14, while TC3-4 showed the strongest similarity to transiently-amplifying cell types and 
TC5 shared similarity with both, transient-amplifying and stem cells. Transcriptome-based cell cycle 
analysis revealed that TC1 is highly proliferative (Fig. 2F). Furthermore, TC clusters shared a couple of 
defining genes that have previously been linked to oncogenic processes in CRC (Supplementary Fig. 4; 
Supplementary Table 1). The CRC stem cell marker CD4416 was expressed prominently in TC1 and TC4. 
MMP7, encoding a matrix metalloproteinase responsible for CRC invasion11, was expressed highest in 
TC4, but also in TC1 and TC3. VIM17 and S100A418, key markers of the epithelial-to-mesenchymal 
transition, were among the genes defining TC2. PLA2G2A, encoding a phospholipase that controls 
inflammation and homeostasis in the intestinal stem cell niche19, and the intestinal stem cell marker 
OLFM4 was overrepresented in TC5. 
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We annotated immune transcriptome clusters by lineage-specific marker genes (Fig. 2A, 
Supplementary Fig. 5). Two main clusters of myeloid cells were assigned as monocytes and 
macrophages by expression of CD14 and CD68. ITGAX (encoding CD11c) was also expressed in this 
domain of the UMAP, indicating that these clusters, in addition, also encompass dendritic cells. A large 
cluster of T cell profiles, as identified by CD3, could be subgrouped into CD8-positive cytotoxic T cells 
and CD4-positive T helper cells. Subclusters of conventional and regulatory T helper cells were assigned 
by higher relative levels of IL7R (encoding CD127), FOXP3 and IL2RA (encoding CD25). B cell and plasma 
cell clusters were defined by CD19, MS4A1 (encoding CD20) and SDC1 (encoding CD138), respectively. 
Among T, B, and plasma cells we could distinguish several subclusters that were represented in tissue 
samples across the patients. Six of the 26 immune cell clusters in our analysis were expanded in all 
eight CRC. These comprise the macrophage/monocyte clusters, regulatory T cells, two clusters of 
plasma cells (termed Plasma 5 and 8, see Supplementary Table 2) and one cluster of CD8-positive T 
cells expressing high levels of IL17A (CD8+ cluster 4, Supplementary Table 2). This interleukin has been 
implicated in CRC progression20, and a similar type of T cell was recently found expanded in single-cell 
analyses of colitis patients14.  
Among stromal transcriptomes, we annotated an interconnected supercluster of fibroblasts.  
Strikingly, one fibroblast cluster was confined to the tumor samples and was therefore designated as 
cancer-associated fibroblasts (CAFs). CAF transcriptomes were defined by high expression of matrix 
metalloproteinase-encoding genes such as MMP1, MMP11, MMP3 and MMP2, suggesting roles of 
these cells in the degradation of the tumor extracellular matrix. The fibroblast supercluster, in addition,  
contained profiles of putative crypt base fibroblasts of the stem cell niche expressing the Wnt ligand 
WNT2B and the Wnt amplifier RSPO321,22, upper crypt fibroblasts expressing genes such as BMP2 and 
BMP4 encoding differentiation-associated growth factors23 (Fig. 2A, Supplementary Fig. 6, 
Supplementary Table 3) and a further small cluster of fibroblasts positive for various chemokine ligands 
and receptors including CCL2, CCL8, CCL11, CCL13, CXCL1 and CXCL14. Further distinct clusters of 
stromal cells were composed of myofibroblasts, possibly intermingled with smooth muscle cells, 
expressing ACTA2 and DES and pericytes marked by MCAM (encoding MUC18/CD146) and STEAP4. We 
also detected small numbers of endothelial cells and glial cells, respectively. Pericytes and endothelial 
cells were more frequent in the tumor samples, but, in contrast to CAFs, these cells were also present 
in normal tissue samples at low frequencies. 
Paracrine signaling in CRC ecosystems 
As we discovered multiple clusters of epithelial tumor cells (TC1-5) and expanded clusters of stromal 
and immune cells in their microenvironment, we investigated possible paracrine interactions. For this, 
we mapped cognate ligand-receptor pairs in our single-cell data, taking into account expression levels 
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of ligands, the prevalence of the ligand-expressing cell (that is, cluster size for that cell type), and 
fractions of receptor-expressing cells. We focused on ligand-encoding genes active in immune or 
stromal cells and genes encoding matching receptors in proliferative epithelial cells, that is, in stem/TA 
cells and the five tumor-specific clusters TC1-5 (Fig. 3A, Supplementary Fig. 7A, and Supplementary 
Table 4). Possible ligand-receptor connections appeared relatively sparse in the normal tissue. 
However, we found many more potential paracrine signaling connections in the tumor. This was mainly 
due to three features of the tumor ecosystem: Firstly, CRC contained novel epithelial cell types TC1-5 
expressing multiple receptors, including high levels of the receptor tyrosine kinase MET24 and others 
(Supplementary Fig. 7B). Secondly, several immune and stromal cell populations expressing cognate 
ligands for the receptors in the epithelium were expanded (Supplementary Figs. 3 and 7B; 
Supplementary Table 5). In particular, CAFs dominated signaling in the microenvironment of tumors 
P008 and P016, and, to a lesser extent, P007 and P017, and express genes encoding ligands of cancer-
relevant signaling pathways. Among these are GREM1, WNT2B, WNT5A, HGF, multiple EGFR ligands 
including AREG and many others that have been linked to CRC initiation and progression25–28. Finally, 
some cell types in the cancer microenvironment expressed additional ligands compared to their 
normal tissue counterparts, for instance, crypt-base-like fibroblasts in the tumor express FGF7 and IGF 
(Supplementary Fig. 7B).  
We took a detailed look at Wnt signaling, as this pathway drives stem cell maintenance and tumor 
initiation in the gut. A signature of Wnt/β-catenin target genes was most active in the TC1-5 and stem 
cell compartment of tumor epithelium (Fig. 3B), while activity was lower among the differentiated CRC 
cells, similar to the normal colon epithelium. Indeed, it has been shown that Wnt/β-catenin is dynamic 
in CRC and can be activated by Wnt ligands29,30, although the pathway is frequently activated by loss 
of APC. We detect the highest connectivity for Wnts and the R-Spondin family of Wnt amplifiers 
between CAFs, expressing WNT2 and WNT5A, and stem cells and the tumor-specific cell clusters (Fig. 
3A). 
We next investigated EGFR-RAS-RAF-ERK signaling that plays a central role in CRC development and is 
a key target of therapy. ERK-regulated genes31 were most active in TC4 (Fig. 3B). We identified CAFs, 
endothelial cells, but also immune cells as potential sources of EGFR family ligands in the CRC 
microenvironment (Fig 3A). Monocytes and macrophages that we found consistently enriched in 
tumor versus normal tissues, express the ligand-encoding genes AREG, EREG, and HBEGF (Fig 3C and 
Supplementary Table 3). These ligands could play roles in the activation of the EGFR-RAS-RAF-ERK 
cascade in CRC, particularly in tumors lacking mutations in RAS, RAF or other activating components 
of the pathway. Macrophages and CAFs also express HGF, encoding the MET receptor tyrosine kinase 
ligand driving cancer progression at the invasive tumor front13. Indeed, we found macrophages to be 
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enriched in tumors specifically at the invasive front (Fig. 3C, D), suggesting that these could play roles 
in the induction of epithelial-mesenchymal transition via HGF-MET. 
We additionally detected TGF-β target gene activity, along with expression of a gene signature of 
epithelial-to-mesenchymal transition in the tumor cell cluster TC4, and to a lesser degree in TC2 (Fig. 
3B, E). Genes encoding TGF-β ligands were expressed in multiple stromal cell types, including CAFs, 
and cognate receptors were present in the TC clusters (Fig. 3E, Supplementary Fig. 7A, B). While the 
connectivity of the TC2 cluster was generally low, maybe also due to lower sequencing depth per cell, 
the cluster was defined by expression of VIM and S100A4 (see above, Supplementary Fig. 4 and 
Supplementary Table 1), supporting the association of TC2 cells with the epithelial-to-mesenchymal 
transition. Interestingly, the size of cluster TC2 was highly correlated with the size of the CAF 
population in the cancer microenvironment in the eight tumor profiles (Fig. 3F), suggesting a potential 
role for CAFs in the support of the tumor cells clustering in TC2.   
Cell type composition informs Consensus Molecular Subtypes 
Consensus molecular subtypes (CMS) represent a transcriptome-based classification system for CRC 
with clinical utility32. We applied the CMS classifier to our single-cell data and found strong inter- and 
intratumor heterogeneity. Epithelial cells were exclusively assigned to CMS1-3 (Fig. 4A). The 
continuous cluster comprising intestinal stem cells, TA cells, and enterocytes of the normal tissue, as 
well as the TC1-5 tumor cell subtypes consists mainly of intermingled CMS1 and CMS2 cells. In our 
limited set of CRCs, we find that epithelial cells of the two cancers probably arising via serrated 
precursors (P007) or inflammation-induced progression (P008) are scoring predominantly CMS1, while 
epithelial cells of the other cancers score mainly as CMS2 (Supplementary Fig. 7). CMS3 appears to be 
confined to cells differentiating into the secretory lineage. 
CMS subtypes were also unevenly distributed in the tumor microenvironment. Almost all immune cells 
were assigned CMS2, and only a minority scored as the “immune” subtype, CMS1 (Fig. 4B). Stromal 
cells were mostly CMS2, but a minority population of normal fibroblasts that we assigned previously 
as potential crypt base fibroblasts were CMS4 (Fig. 4C). Most interestingly, CAFs in the tumor tissue 
provided a strong CMS4 component that in our tumors was most prominent in P008 and P016 
(Supplementary Fig. 7). As CMS4 was assigned to fibroblasts exclusively, we suggest that this cell type 
also drives the “mesenchymal” CMS4 assignment from bulk CRC tissue. It is of note that CMS4 cancers 
have a worse clinical prognosis which may, therefore,  also be linked to the presence of stromal tumor-
specific fibroblasts. In summary, we found that different cell types of the tumor ecosystem are 
preferentially assigned to different CMS, and thus, that bulk tissue CMS assignments report 
combinations of cell state and cell type prevalence in the tumor.  
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Cell type composition of patient-derived CRC organoids and matched tumor samples 
We established organoid lines of the tumor samples P009 and P013, using standard culture conditions 
with media containing EGF, FGF, and p38- and TGF-β inhibitors (Fig. 5A)33,34. P009 tumor tissue initially 
grew out unevenly, however, formed a uniformly spheroidal organoid culture within three passages. 
P013 tumor tissue grew out swiftly and uniformly, forming complexly folded organoids. We used panel 
sequencing to confirm the identity of the organoids with the matched tumor tissue on a mutational 
level (Supplementary Table 6). 
We used cell suspensions of the organoid lines for single-cell RNA sequencing to generate profiles 
before the first passage (designated as p0), essentially sequencing the primary tissue after one to two 
weeks of expansion in culture. We also sequenced transcriptomes of the established lines P009 and 
P013 after two and three passages, respectively. Single-cell profiles of organoids were of a higher 
quality than those from epithelial cells of the tumors, as judged by the uniformly low fraction of 
mitochondrial reads, despite having used similar conditions for disaggregation at 37°C. To exclude 
confounding effects of technical differences in the different single-cell profiles, we anchored the 
organoid profiles in the space of the matched epithelial tumor transcriptomes35. 
In the resulting integrated data set, organoid cell transcriptomes of the two patients and the different 
passage numbers intermingled (Fig. 5B). Next, we re-clustered the transcriptomes and assigned cell 
identities per cluster by matching cell types with the previous annotation (Fig. 5C, D; for the previous 
annotation, see Fig. 2A, B). We found that profiles corresponding to TA cells, differentiated cells, and 
the tumor-specific TC1-TC5 cell types were present in the organoids. Stem cells, tuft cells and 
BEST4/OTOP2-positive enterocytes, which are all cell types that were present only in small numbers in  
the original primary tumor samples, were not called in any organoid single-cell library. Surprisingly, 
despite the different phenotypic appearance of the organoid cultures, cell type distributions were very 
comparable. In particular, TC cell types were present at similar fractions regardless of organoid line 
and passage number, unlike the dissimilar TC cell type ratios in the matched tumors. In all four 
organoid libraries, the highly proliferative TC1 cell type was overrepresented compared to the matched 
tumors.  
Differentiation trajectories of CRC organoids  
As all major epithelial cell types were present in the organoids, we used the transcriptomes to establish 
how the tumor cells are related to each other within differentiation trajectories. We used diffusion 
maps to take into account a pseudotemporal order of the transcriptomes that is related to cell 
differentiation. Profiles of both organoid lines ordered into a structure containing cells expressing stem 
cell markers such as LGR5, PROM1 or CD44 merging into an extended projection containing cells 
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positive for the absorptive and secretory differentiation markers FABP1 and TFF3 (Supplementary Fig. 
9). Markers specific for the TC cell clusters, that is, MMP7, S100A4, and VIM were found overlapping 
and adjacent to the stem cell zone defined by LGR5, PROM1 and CD44.  
The organoid line P009 showed an enlarged zone inhabited by transcriptomes positive for the TC cell 
markers and was, therefore, suitable to infer a more granular picture of cell plasticity by taking into 
account RNA velocity, that is, direction of cell differentiation defined by ratios of immature unspliced 
versus mature spliced mRNAs (Fig. 5E). We could define a single trajectory origin in the vicinity of cells 
expressing the normal intestinal stem cell marker LGR5 and CD44, which is a CRC stem cell marker 
highly expressed in TC1. The main differentiation trajectory extended towards the FABP1- and TFF3-
positive differentiated cells. A shorter trajectory stretched towards the area with the highest 
expression of the TC4 cell marker MMP7. We conclude that the TC cells can inhabit a zone of cell 
plasticity encompassing CRC stem cells and progenitor-like descendants that are, however, distinct 
from absorptive or secretory progenitors.  
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Discussion  
Here, we use droplet-based single-cell sequencing of transcriptomes to characterize patient-derived 
matched CRC and normal colon tissue, as well as CRC organoids. We find that CRC, regardless of specific 
genetic mutations or clinical parameters, contains a large proportion of tumor-specific 
undifferentiated epithelial cells in addition to cells that resemble differentiated cell types of the normal 
colon epithelium. We assign the tumor-specific epithelial cells to five clusters, TC1-5, that form a 
continuum of cell plasticity. The TC cell types are distinguished by proliferative activity, oncogenic 
signaling, and gene expression patterns related to stemness, tissue invasion, and epithelial-to-
mesenchymal transition. We conclude that these cancer traits are unevenly distributed between 
tumor cell subpopulations. Furthermore, we identify stromal and immune cell types, including CAFs, 
macrophages, monocytes, and subsets of CD8+ T cells as cell types enriched in the tumor 
microenvironment that are sources of multiple growth factors initiating or amplifying Wnt-, TGF-β-, 
EGFR- and HGF-MET-signaling. This data suggest that paracrine signaling is a defining factor shaping 
the CRC ecosystem. 
Our single-cell analysis illuminates a couple of clinically relevant features of CRC. Classification of CRC 
by bulk cancer transcriptome analysis can be achieved by the consensus molecular subtype system32. 
CMS4, also termed as the “mesenchymal” subtype, is notable for its worse relapse-free and overall 
survival. We show here on a single-cell level that CMS4 transcriptomes stem specifically from 
fibroblasts, in particular, CAFs, while epithelial tumor cells can only assume CMS1 - CMS3. We 
conclude, therefore, that CMS4 is assigned to CRCs with a high content of CAFs that could possibly also 
contain a large fraction of the correlated TC2 tumor cell subtype. As we find CAFs to produce multiple 
pro-oncogenic growth factors including HGF and TGF-β ligands, it appears as a plausible strategy to 
target paracrine signaling as a future therapeutic option for the CMS4 CRC subtype. Furthermore, we 
could assign epithelial differentiation states to CMS subtypes. Our findings could be used to 
incorporate further informative and cell-type-specific genes into the CMS classifier, in order to assign 
CRCs with greater specificity, including those CRCs that currently cannot be assigned to a CMS subtype.  
Anti-EGFR antibodies serve as first-line targeted therapy for patients with metastatic disease and no 
mutations in the EGFR-RAS-RAF-ERK signaling axis. Treatment success in this cohort has been linked to 
the production of the EGFR ligands AREG and EREG, and to immune infiltration in separate 
publications28,36. Connecting these phenomena, we have identified here AREG and EREG to be 
expressed by immune cells in the CRC ecosystems that we investigated here, in addition to epithelial 
cells. AREG and EREG were most strongly active in monocytes, and AREG was additionally expressed 
in other immune cell types. We hypothesize that AREG-/EREG-expressing immune cells contribute to 
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the paracrine signaling loop activating ERK in KRAS-, NRAS- and BRAF-wildtype CRC cells, and possibly 
influence anti-EGFR antibody therapy outcome. 
Our results imply that CRC cells display considerable cell plasticity and have multilineage differentiation 
capacity, in agreement with pioneering single-cell sequencing studies37,38.  Stem cells have traditionally 
been seen as unique cells driving tissue homeostasis and regeneration of normal tissue, but also 
therapy-resistance in cancer. However, recent studies have shown that combinations of oncogenic 
mutations and paracrine signals can steer the cell-intrinsic signaling network so that differentiation 
trajectories are reversed and more differentiated cells can regain stem cell characteristics39–43. In CRC, 
stem cells can be maintained and induced by factors such as HGF13 and IL17A20. We found 
Macrophages and CAFs to express HGF and EGFR ligands, extending previous observations44,45. We also 
observed an expansion of IL17A-expressing CD8+ T cells. As these cells also showed transcription of 
KLRB1, these cells might be mucosal-associated invariant T cells (also known as MAITs)46,47. To verify 
this, an analysis of the invariant T cell receptor Valpha7.2 could be performed in future studies. 
Some tumor samples in our analysis contained a small proportion of normal epithelial tissue (see 
Supplementary Fig. 1). To ascertain the origin of transcriptomes assigned to differentiated epithelial 
cell clusters, we calculated probabilities for single-cell transcriptomes to be derived from the tumor, 
taking into account RNA reads covering somatic mutations. While this approach successfully assigned 
a small fraction of transcriptomes as deriving from normal or tumor cells, respectively, a large majority 
of single-cell profiles remained unassigned (Supplementary Fig. 10). We conclude that single-cell 
transcriptomes acquired by our droplet-based sequencing platform contain insufficient information 
for mutation-based tumor cell assignment. However, several lines of evidence support that CRC 
contains many cells similar to normal differentiated cell types: firstly, we find enterocyte- and goblet 
cell-like transcriptomes in tumor samples, but tuft cells and BEST4/OTOP2-positive enterocytes are 
selectively depleted, arguing against normal tissue contamination. Secondly, we could stain a 
substantial proportion of tumor cells using antibodies against the goblet cell and enterocyte 
differentiation markers TFF3 and FABP1, respectively. Thirdly, organoids cultured in a medium 
supporting the specific outgrowth of tumor cells maintained differentiated cell populations, with the 
exception of tuft cells and BEST4/OTOP2-positive enterocytes. 
In organoid cultures, the complex in vivo microenvironment is substituted by a uniform extracellular 
matrix and only a few growth factors. It has not been examined in detail how organoid culture 
conditions affect tumor cell heterogeneity compared to the tissue of origin. We show here that CRC 
organoids maintain all main cell types of CRC, including the tumor-specific cell types TC1-TC5, in the 
absence of stromal or immune cells. However, organoids were enriched for profiles of the strongly 
proliferative TC1 cells in both patient-derived cultures and multiple passages, probably reflecting the 
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growth conditions with high concentrations of EGF, but lacking a complex cellular microenvironment 
(see Fig. 5D). It is of note that improved experimental procedures are now available incorporating 
fibroblasts into organoid cultures to better mimic paracrine interactions present in vivo48. Single-cell 
analysis of such models could inform the dissection of cellular interdependences in CRC, and would 
also provide a more realistic scenario for preclinical drug tests. 
Our workflow for dissociating clinical samples resulted in the acquisition of many types of major 
epithelial, immune and stromal cell transcriptomes. In addition, we capture subtle transcriptome 
differences within T cells, plasma cells, fibroblasts, and the tumor-specific TC cells that were assigned 
to multiple similar clusters. Analysis of single-cell transcriptomes is subject to multiple confounding 
factors, including numbers of genes detected, fractions of spliced versus unspliced mRNAs, and the 
fraction of mitochondrial reads. Indeed, particularly the epithelial cell transcriptomes that we captured 
for the present study varied on these quality parameters within, but also between the clusters. 
Reassuringly, the distinction of phenotypic features between clusters was largely independent of the 
confounders. However, we note that the discrimination of five tumor-specific epithelial clusters is 
purely heuristic and, presently, we consider tumor-specific epithelial cells to have continuous 
phenotypic plasticity rather than inhabiting fixed states that can be clustered with confidence.  
Improvements to methods for tissue dissociation have recently been published49 and should be 
incorporated into future clinical workflows to diminish tissue processing artifacts. However, with 
clinical samples, cell-type-specific degradation of transcriptome quality during the ischemic time 
window between the restriction of blood flow and completion of the operation probably cannot be 
avoided completely.  
The extension of single-cell analyses of CRC to multi-omics, taking also in account genetic and 
epigenetic heterogeneity50,51, promises to identify cell plasticity and genetic diversity in cancer at a 
cellular resolution. We believe that such approaches will aid the future identification and eradication 
of CRC cell populations responsible for therapy resistance. 
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Methods 
Acquisition and processing of clinical specimens  
Fresh normal colon and colorectal cancer tissues were acquired during the intraoperational 
pathologist´s examination. Tissues (approx. 0.1-0.4g) were minced using scalpels and stored short-
term on ice in Tissue Storage Solution (Miltenyi # 130-100-008) for transport. Next, tissues were 
processed using the Miltenyi human Tumor Dissociation Kit (Miltenyi, #130-095-929) and a Miltenyi 
gentleMACS Octo Tissue Dissociator with heaters (Miltenyi, #130-096-427), using program 
37C_h_TDK_1 for 30-45min. Cell suspensions were filtered using 100µm filters, and all subsequent 
steps were performed at 4°C or on ice. Cells were pelleted by centrifugation in BSA-coated low-binding 
tubes, and cells were treated with 1ml ACK erythrocyte lysis buffer for 60 seconds and washed with 
DMEM. Cells were pelleted, resuspended in PBS, cell suspensions were filtered using 20µm filters, 
debris was removed using the Debris Removal Solution (Miltenyi #130-109-398), and cells were 
counted using a Neubauer chamber. At least 104 cells of all suspensions were analyzed for cell viability 
>75% using LIVE/DEAD Fixable Dead Cell Stain Kit (488nm; Thermo Fisher) and a BD Accuri cytometer. 
Hematoxylin-and-eosin staining and immunostaining 
3-5 µm tissue sections of fresh frozen or formalin-fixed and paraffin-embedded (FFPE) tissue were used 
for immunofluorescence, immunohistochemistry and hematoxylin and eosin staining. 
Immunohistochemical and immunofluorescence stainings of FFPE tissue sections were performed on 
the BenchMark XT immunostainer (Ventana Medical Systems). For antigen retrieval, tissue sections 
were incubated in CC1 mild buffer (Ventana Medical Systems) for 30 min at 100°C. Sections were 
incubated with primary antibodies for 60 min and with secondary antibodies for 30 minutes at room 
temperature diluted in Dako Real Antibody Diluent (Dako, S2022). The following primary antibodies 
were used: rabbit anti-TFF3 (1:250, Abcam, ab108599), mouse anti-FABP1 (1:1000, Abcam, ab7366), 
rabbit anti-OLFM4 (1:100, Atlas Antibodies, HPA077718), mouse anti-EPCAM (1:100, ThermoScientific, 
MS-144-P1), rabbit anti-Ki67 (1:400, Abcam, ab16667), mouse anti-Ki67 (1:50, Dako, M7240), mouse 
anti-CD68 (1:100, Dako, M0876). Images were taken using an Axio Vert.A1 fluorescence microscope 
(Zeiss) equipped with an Axiocam 506 color camera (Zeiss). 
Single-cell RNA sequencing 
104 single cells were used for single-cell library production, using the Chromium Single Cell 3´Reagent 
Kits v3 and the Chromium Controller (10x Genomics). Libraries were sequenced on a HiSeq 4000 
Sequencer (Illumina) at 200-400mio. reads/library to a mean library saturation of 50%. This resulted in 
35.000 to 120.000 reads per cell. 
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DNA Sequencing 
For panel sequencing for frequent oncogenic driver mutations, tumor-enriched areas (> 40 % tumor 
cells) were macrodissected from FFPE tissue sections, DNA was extracted using the Maxwell RSC DNA 
FFPE Kit (Promega) and sequenced using the Ion AmpliSeq Cancer Hotspot Panel v2, and an IonTorrent 
sequencer (ThermoFisher) according to the manufacturer’s instructions. For variant calling the 
Sequence Pilot Software (Version 4.4.0, JSI Medical Systems) was used. For the sequencing of exomes 
(patients P007, P008, P009), DNA was isolated from fresh frozen tumor tissue after the pathologist´s 
examination using the DNeasy Blood and Tissue Kit (Qiagen). Exomes were sequenced using the 
AllExon Human SureSelect v7 Kit (Agilent). 
Organoid Culture 
Cell filtrates from patient-derived tumor tissues that were retained in the 20µm filters after 
dissociation were washed in Advanced DMEM/F12 medium (Gibco), embedded in Matrigel, and 
cultured in 24-well plates, according to published procedures. Rho-kinase inhibitor Y27632 (10µM, 
Sigma) was used for the first passage to avoid anoikis. Cells originally embedded in Matrigel (Corning) 
were termed passage 0 (p0), and outgrowing organoids were passaged by removal from Matrigel, 
washing in PBS, and partial digestion using TrypLE cell dissociation solution (Gibco) at 37°C, washing in 
medium and re-embedding in Matrigel. For single-cell sequencing, organoids were dissociated 
completely using TrypLE and DNAseI, and filtering via a 20µm filter. 
Single-cell RNA-seq data analysis 
For each sample, UMIs were quantified using cellranger 3.0.2 with reference transcriptome GRCh38. 
Spliced, unspliced and ambiguous UMIs were quantified with velocyto52 (mode: run10x, default 
parameters). Quality control filters were set to only include cells with 500 to 5000 genes detected, 
1000 to 50000 UMIs counted, fraction of mitochondrial reads ranging between 0 and 0.8, fraction of 
spliced reads ranging between 0.3 and 0.9, fraction of unspliced reads ranging between 0.1 and 0.7 
and fraction of ambiguous reads ranging between 0 and 0.2. After filtering, UMI counts were variance-
stabilized using scTransform53, while regressing out fractions of mitochondrial reads and differences in 
S-Phase and G2M-Phase scored with Seurat v335. Next, main cell types (epithelium, stromal, and 
immune cells) were identified by scoring cell type markers across Louvain clusters for each sample 
(resolution = 1).  In samples where more than 2000 cells were assigned to a certain cell type, a random 
sample of 2000 cells was used of this cell type for the given sample. Normalized subsets were merged 
for each main cell type of normal and tumor samples without further batch correction. Louvain cluster-
specific marker genes of merged normal and tumor samples were used to identify sub cell types among 
epithelial, stromal and immune subsets. Gene expression sets were taken from the hallmark signature 
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collection of the Broad institute54, unless otherwise referenced in the main text, and were scored with 
Seurat v3. Epithelial subsets of tumor and matched organoid samples were integrated using Seurat v3 
with tumor samples as reference35. Consensus molecular subtypes were scored using random forrest 
approach included in R package CMSclassifier.  
Diffusion map analysis and RNA velocity were performed using scanpy55 and scvelo56. Cells were first 
filtered by the number of genes (between 2000 and 5000) and the percent mitochondrial reads 
(between 0.075 and 0.2) and normalized, using scvelo standard settings. Cell cycle was scored 
according to the scanpy tutorial, and S_score, G2M_score, percent mitochondrial reads and UMI 
counts per cell were regressed out. The diffusion map was calculated on the top 10 principal 
components, and using a neighborhood graph with 50 neighbors and calculated on all genes. Moments 
were calculated on 30 principal components and 30 neighbors, and velocity was calculated using the 
stochastic model. 
To compute ligand-receptor connectivity between cell type clusters, UMI counts were summed for all 
ligands of the same pathway in each stromal or immune cell type of normal or tumor samples. Summed 
ligand counts were scaled to range between zero and one for each pathway. The fraction of normal 
and tumor proliferative epithelial cells expressing a given receptor was calculated and fractions were 
averaged across receptors for each pathway and cell type. Averaged fractions of cells expressing 
receptors were likewise scaled to range between zero and one for each pathway. Connectivity 
between stroma or immune ligand expression and epithelial receptor expression was calculated as the 
product of scaled ligand counts and scaled receptor expression fractions and, accordingly, also ranged 
between zero and one. 
Tumor cell calling 
For tumor-specific single-nucleotide variant (SNV) calling on single-cell data, we employed exome 
sequence data of patients P007, P008 and P009. We used Mutect257 to detect SNVs, retaining only 
events classified as somatic. We additionally filtered these results by removing variants on non-
canonical chromosomes or within repeat regions (UCSC genome browser RepeatMasker track). We 
then used cellSNP 58 to quantify the total number dij of (UMI-collapsed) reads covering variant i in cell 
j (reference and variant allele), and the number aij of reads supporting the alternative allele, using all 
variants detected with at least one read in any cell, and all cells containing at least 3 variant-covering 
reads. Adapting the EM-type approach proposed in McCarthy et al.59 to our situation, we evaluate the 
likelihood pT,j that cell j is a tumor cell using a binomial model:  
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Here, θT is the "success probability" for the somatic variants, measuring how likely it is to get a read 
supporting the variant allele. Similarly, we compute pN,j as the likelihood that cell j is normal, with a 
fixed parameter θN=0.01 allowing for sequencing errors and uncertainties in the variant calls. We 
calculate pT,j and pN,j in the E-step and estimate the parameter θT in the M-step as weighted sum over 
the counts dij and aij:  
E- and M-steps are iterated until convergence of the likelihood  
 Finally, the criterion pT,j > pN,j is used to define likely tumor cells.   
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Figure 1: Generation and initial assignment of CRC single-cell RNA sequencing data. A Clinical data 
for the eight patients under investigation in this study. For mutational data, see also Supplementary 
table 6. Loc (Localisation): C: cecum; S: sigmoid colon; T: transverse colon; A: ascending colon; R: 
rectum. Prog (Predicted Progression): S: via serrated precursor; I: inflammatory/colitis-associated; C: 
canonical. Tissues used for single-cell RNA sequencing: N: Normal; T: Tumor; O: Organoid. B UMAPs of 
epithelial, immune and stromal cells, color-coded for patients. C UMAPs of epithelial, immune and 
stromal cells, color-coded by tissue of origin. 
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Figure 2: Cell type census in normal colon and CRC. A UMAPs of epithelial, immune and stromal cells, 
separated by tissue of origin. Color code for cell type assignment. B Relative fractions of epithelial, 
immune and stromal cell types across all patient-derived libraries. For fractions per patient, see 
Supplementary Figure 3. C Single cell gene activities of stem cell marker OLFM4, proliferative marker 
MKI67, differentiated absorptive cell marker FABP1, and secretory cell marker TFF3. D 
Immunofluorescence analysis for OLFM4, MKI67, FABP1, and TFF3 in normal and tumor tissue. All 
sections are from patient P009, except the EPCAM/OLFM4 co-staining that was done on tumor tissue 
of P016. Scale bars indicate 100µm. E Relative fraction of TC1-5 in the tumor tissues of the patients. F 
Transcriptome-inferred cell-cycle distribution in the tumor cell fractions TC1-TC5 (bar graph), and in 
the UMAPs of normal and tumor epithelium.  
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Figure 3: A connectivity map of potential paracrine interactions in CRC. A Connectivity analysis for 
ligand expression in stromal and immune cells, and receptor expression in proliferative epithelial cell 
clusters. Connectivity takes into account expression levels of ligands, the prevalence of the ligand-
expressing cell, and fractions of receptor-expressing cells. See methods for details. Circle sizes: Cell 
numbers for ligand-expressing cells, as in figure legend. Red: High connectivity; grey: low connectivity. 
B Activities of Wnt, ERK and TGFβ target genes in the UMAPs of normal and tumor epithelium. C 
Expression of key ligands for CRC progression and therapy response in immune cells. D 
Immunohistochemistry for macrophages in normal and tumor tissue of P009, using an antibody against 
CD68. In the tumor, macrophages are more prevalent, in line with the single-cell data. Macrophages 
are enriched at the invasive front (tumor, to the right). Scale bar indicates 100µm. E Activity of 
receptors implicated in the epithelial-to-mesenchymal transition, and activity of genes comprising the 
EMT hallmark signature. F Correlation between fractions of CAFs in the stromal cell compartment and 
TC2 tumor cells in the epithelial tumor compartment.  
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Figure 4: Consensus molecular subtype analysis on the single-cell level. A CMS calling on cells of the 
epithelial compartment. B CMS calling on cells of the immune compartment. C CMS calling on cells of 
the stromal compartment. In all subfigures, CMS subtypes are mapped to the normal and tumor tissue 
UMAPs to the left, and posterior probability scores for the complete tumor and normal cells in the 
respective compartments per patient are given to the right. 
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Figure 5: Epithelial cell types in matched tumors and organoids. A Phenotypes of organoid lines 
established from study patients. Patient and passage number are given to the left. B UMAPs of tumor-
derived epithelial tissue profiles and anchored organoid profiles, color coded for sample type, patient, 
organoid passage number and cell cycle phase, as indicated. C UMAPs of tumor epithelial and organoid 
cells, color-coded by cell-type assignment. D Cell type distributions in tumor tissue and organoids. E 
RNA velocity of organoid line P009. Cells highly expressing the enterocyte marker FABP1, the normal 
stem cell markers LGR5 the TC1 stem cell marker CD44, and the TC4 tumor cell marker MMP7 are 
highlighted by green, blue and red and rose color, respectively. Arrows indicate two trajectories with 
a common root near the LGR5- and CD44-expressing cells, and extending towards the FABP1 and 
MMP7-positive cells. 
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